Shingrix vaccine linked to lower heart disease risk

Full analysis

A major study found that people who received two doses of the Shingrix shingles vaccine had a 9% lower risk of serious heart-related problems over seven years compared to those who received the older Zostavax vaccine. The finding adds a potential cardiovascular benefit to the already well-established reason to get vaccinated — preventing a painful shingles outbreak. Adults 50 and older are the primary target group for shingles vaccination, so this research is directly relevant to that age group's vaccination decisions.